Kucers, A., Scrowe, S., Grayson, M.L., et al. (1997) The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, and Antiviral Drugs. 5th Edition, Butterworth-Heinemann, Boston, MA.

has been cited by the following article:

• TITLE: Comparative Study of the Mutant Prevention Concentrations of Sulfamethoxazole-Trimethoprim Alone and in Combination with Levofloxacin against Stenotrophomonas maltophilia

  AUTHORS: Xihai Xu, Xi Chen, Nian Sun, Jun Yin, Jiabin Li

  KEYWORDS: Stenotrophomonas maltophilia, Mutant Prevention Concentration, Sulfamethoxazole-Trimethoprim, Levofloxacin

  JOURNAL NAME: Advances in Infectious Diseases, Vol.7 No.2, June 22, 2017

  ABSTRACT: Objectives: To determine the mutant prevention concentration (MPC) of sulfamethoxazole-trimethoprim (SXT) alone and in combination with levofloxacin (LVX) against Stenotrophomonas maltophilia (S. maltophilia) and to determine if the combination may decrease the emergence of resistant mutants. Methods: The MPC with 20 S. maltophilia strains which were both susceptible to SXT and LVX were determined by inhibiting visible growth among 1010 CFU on four agar plates after 72 hours incubation at 37°C. Results: All except two strains (18/20) showed a mutant prevention concentration ≥ 152/8 μg/mL for SXT and the range of the mutant prevention concentration for the SXT in combination with LVX is 9.5/0.5~608/32 μg/mL, which demonstrates at least 2 fold reduction except one strain. There was a significant difference (P Conclusions: The MPC/MIC values were narrowed for SXT by combining with LVX against the S maltophilia. The combination may decrease the enrichment of mutant bacterial populations. Much study is needed to verify whether the using of drug combinations may restrict or even block the selection of S. maltophilia mutants.